Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Capital Expenditures readings, the most recent being $108000.0 for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 217.65% to $108000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $157000.0, a 84.71% increase, with the full-year FY2025 number at $83000.0, down 45.75% from a year prior.
  • Capital Expenditures hit $108000.0 in Q1 2026 for Kiniksa Pharmaceuticals International, up from -$852000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $597000.0 in Q3 2025 to a low of -$852000.0 in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $34000.0 (2023), compared with a mean of $33142.9.
  • The widest YoY moves for Capital Expenditures: up 1788.89% in 2025, down 1334.78% in 2025.
  • Kiniksa Pharmaceuticals International's Capital Expenditures stood at -$32000.0 in 2022, then skyrocketed by 275.0% to $56000.0 in 2023, then grew by 23.21% to $69000.0 in 2024, then crashed by 1334.78% to -$852000.0 in 2025, then surged by 112.68% to $108000.0 in 2026.
  • The last three reported values for Capital Expenditures were $108000.0 (Q1 2026), -$852000.0 (Q4 2025), and $597000.0 (Q3 2025) per Business Quant data.